Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerScott Gettinger, Julie R. Brahmer, Scott Antonia et al.|Journal of Clinical Oncology|2015Cited by 1.2k
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid TumorsGeoffrey Y. Ku, Samuel J. Klempner, Lin Shen et al.|Clinical Cancer Research|2025Cited by 16